Related Experiment Video
Updated: Jun 7, 2026
07:59
Translationally-Relevant Tumor Resection Model for Murine Preclinical Models of Oral Squamous Cell Carcinoma
Published on: April 3, 2026
Induction chemotherapy for head and neck cancer: recent data
1Department of Medicine and Cancer Research Center, The University of Chicago Medical Center, Chicago, Illinois 60637, USA. evokes@medicine.bsd.uchicago.edu
The Oncologist
|November 2, 2010
Summary
Adding chemotherapy to radiotherapy improves survival for head and neck cancer patients. Concurrent chemoradiotherapy offers the greatest survival benefit, while induction chemotherapy aids organ preservation.
Area of Science:
- Oncology
- Head and Neck Cancer Treatment
Background:
- Chemotherapy combined with radiotherapy enhances survival in locally advanced squamous cell carcinoma of the head and neck (SCCHN).
- The timing of chemotherapy administration significantly impacts survival benefits.
Purpose of the Study:
- To review the efficacy of different chemotherapy timings in SCCHN treatment.
- To evaluate the role of induction chemotherapy in organ preservation and survival outcomes.
Main Methods:
- Meta-analyses of randomized trials were examined.
- Comparison of concurrent chemoradiotherapy, induction chemotherapy followed by radiotherapy, and locoregional treatment alone.
Main Results:
- Concurrent chemoradiotherapy provides the most significant survival advantage over locoregional treatment.
- Induction chemotherapy, particularly with platinum and 5-fluorouracil (PF), shows survival benefits and aids organ preservation.
- Triplet induction regimens (docetaxel, cisplatin, 5-fluorouracil) are more effective than doublet PF regimens.
Conclusions:
- Concurrent chemoradiotherapy is optimal for survival in locally advanced SCCHN.
- Sequential chemotherapy strategies, including induction regimens, are valuable for organ preservation and offer survival benefits.
- Ongoing trials investigate the addition of induction chemotherapy to standard chemoradiotherapy.
Related Concept Videos
01:28Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates these...
01:27Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists
5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
02:49Cancer Therapies
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
02:56Treatment Resistent Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
02:56Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...